MET vs PCRX · P/E 13, rev $38.23B vs P/E 174, rev $369.8M
MetLife Inc (MET) versus Pacira BioSciences, Inc. (PCRX) — a side-by-side from cached financials, not a winner call.
MetLife Inc (MET) is a insurance - life company listed on US.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported MET revenue for 2026-06-30 was $38.23B. Net income was $1.92B. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
MET currently screens at market cap $52.16B and trailing P/E 12.7. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Not investment advice. Open the MET and PCRX stock pages for the full models.
Not investment advice.